40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Información del proyecto

BRIGHT

Identificador del acuerdo de subvención: 867873

DOI

10.3030/867873

Proyecto cerrado

Fecha de la firma de la CE 26 Abril 2019

Fecha de inicio 1 Mayo 2019

Fecha de finalización 30 Septiembre 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

OPTOCEUTICS APS
Denmark

Periodic Reporting for period 1 - BRIGHT (40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease)

Período documentado: 2019-05-01 hasta 2019-09-30

Resumen del contexto y de los objetivos generales del proyecto

One of the major public health challenges worldwide is the rapidly growing number of people with dementia. More than 50 million people worldwide are living with dementia and about 70% of those are diagnosed with Alzheimer’s disease. Although a global burden – equivalent to 1% of the world's GDP – AD is particularly critical in the EU, where over 10.5 million patients live with dementia.
BRIGHT aims to develop 40 Hz flickering light therapy using novel invisible spectral flicker (ISF) that can induce brainwaves in AD patients and potentially improve cognition and potentially slow the disease progression. The light is combined in a way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The primary objective of the project is to validate the need for such a treatment, and establish the necessary partners for the clinical evaluation.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the feasibility study of Phase 1 we gathered tremendous amount of information and uncovered valuable knowledge and understanding, some of which are the following:
- User requirements addressed by subsequent new design features
- Market analysis that identified the most interesting market segment, in regards to effect, willingness and size. This sharpens our eye and approach onwards in regards to product development, strategy and IPR
- Effective and detailed national go-to-market strategy and business model to address the market segment, including supply and sales setup
- Strong partnership with key clinical partners and pilot test participants

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

With the work done in SMEi Phase 1, it is now possible to move directly forward to clinical tests, with a device at that is validated among the users, designed and optimised for regulatory approval.
Furthermore a clear plan of the implementations of the 40 Hz neuromodulation light in a business setting is prepared - Ultimately leading to potentially better health and life among the population.

Optoceutics Logo